Meet QuantaKinome

QuantaKinome™ is a targeted mass spectrometry-based phosphoproteomics technology. This is a highly specific and sensitive technique which selectively quantifies phosphorylated activation loops of protein kinases within complex human samples.

Discover the technology behind our kinome activity phosphoproteomics platforms.

Actionable translation in drug development through in-depth kinase activity profiling.

QuantaKinome™ deeply and directly quantifies the activity of more than one third of the known kinome in its native environment in a single run.

A groundbreaking, targeted MS-based technology for profiling the network activity of endogenous protein kinases in human samples.

QuantaKinome™ features

Your Benefits

Endogenous kinase activity data The most relevant information for compound development
Broadest coverage of pathways Insight in all critical kinome pathway activities
Wide range of sample types One single assay from compound discovery to the clinic
Ultra-sensitive Detection of low-abundant kinases, in smallest possible samples
Ultra-precise quantification Highly reproducible between samples, experiments, patients
Ultra-specific Distinguishes even highly similar kinase isoforms
Multiplex kinetic measurements Monitors pathway activity rewiring and resistance mechanisms over time
Customizable Select your pathway of choice
Fit-for-purpose assay Assay development for RUO and CLIA/FDA/EMA approved

Tune your modelling in various samples & therapeutic areas

Compose your drug development with integrated feedback

You can apply QuantaKinome throughout development phases and between human models to provide you with actionable translation. Measure the same data regardless of where you are and compare data to truly understand human kinome activity.

 

Target

Discovery

Lead Optimization

Pre-Clinical Research

Clinical Research

Tune your PKI MOA game in 4 value-adding steps

4

Off-target activities known

Unforeseen side effects are cought by insight knowledge

3

Pathway engagement confirmed

Downstream pathway inhibition is essential

2

Target engagement confirmed

Endogenous kinase activities are key to successful compounds

1

Set the right assay time window (kinetics)

Conscious timepoints lead to correct drug effect conclusions

Tune your PKI MOA game in 4 value-adding steps

1

Setting the right assay time window

Set the right assay time window (kinetics)

2

Target engagement confirmed

Endogenous kinase activities are key to successful compounds

3

Pathway engagement confirmed

Downstream pathway inhibition is essential

4

Off-target activities known 

Unforeseen side effects are cought by insight knowledge